Journal
CELLULAR SIGNALLING
Volume 73, Issue -, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cellsig.2020.109704
Keywords
Polycystic kidney disease; mTORC1; AMPK; Energy metabolism; Inflammation
Categories
Funding
- Canadian Institutes of Health Research (CIHR)Strategy for Patient Oriented Research (SPOR) Program grant in Chronic Kidney Disease [CAN-Solve-CKD SCA-145103]
- CIHR Foundation [201709FDN-CEBA-116200]
- Diabetes Canada Investigator Award [DI-5-17-5302-GS]
- Tier 1 Canada Research Chair
- J Bruce Duncan Endowed Chair in Metabolic Diseases
Ask authors/readers for more resources
Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenetic kidney disease worldwide and an important cause of chronic kidney disease. Multiple experimental studies have highlighted the role of increased mammalian target of rapamycin complex 1 (mTORC1) and reduced AMP-activated protein kinase (AMPK) signaling in modulating cyst growth in ADPKD. Notably, mTORC1 and AMPK are two diametrically opposing sensors of energy metabolism which regulate cell growth and proliferation. Although pharmacological mTORC1 inhibition was highly effective in experimental studies of ADPKD, clinical trials of mTORC1 inhibitors showed a lack of efficacy with low-dose treatment and poor tolerability with high-dose treatment. Therapeutic AMPK activation has been shown to attenuate cystic kidney disease severity in Pkd1 mutant animal models by improving mitochondrial biogenesis and reducing tissue inflammation. This review summarizes the current knowledge on the function of AMPK as a regulator of cellular energy metabolism and how AMPK activation by pharmacological and non-pharmacological means can potentially be exploited to treat ADPKD in the clinical settings.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available